J&J: agreement with Sanofi for E. coli vaccine
(CercleFinance.com) - Sanofi today announced that it has entered into an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the development and commercialisation of a nine-valent candidate vaccine against extra-intestinal pathogenic strains of E.
coli developed by Janssen.
E. coli strains responsible for extra-intestinal infections (or ExPEC) are one of the leading causes of sepsis and are responsible for approximately 10 million cases of invasive infections per year worldwide, the French healthcare group said.
A Phase III clinical trial of the vaccine candidate was launched in 2021 and is currently underway. This new vaccine against extra-intestinal pathogenic strains of E. coli is expected to round out Sanofi's current portfolio of vaccines for older adults.
Both parties will jointly finance current and future R&D expenses. Sanofi will make an upfront payment of $175m to Janssen, followed by milestone payments based on certain targets. Closing is subject to customary regulatory approvals.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
coli developed by Janssen.
E. coli strains responsible for extra-intestinal infections (or ExPEC) are one of the leading causes of sepsis and are responsible for approximately 10 million cases of invasive infections per year worldwide, the French healthcare group said.
A Phase III clinical trial of the vaccine candidate was launched in 2021 and is currently underway. This new vaccine against extra-intestinal pathogenic strains of E. coli is expected to round out Sanofi's current portfolio of vaccines for older adults.
Both parties will jointly finance current and future R&D expenses. Sanofi will make an upfront payment of $175m to Janssen, followed by milestone payments based on certain targets. Closing is subject to customary regulatory approvals.
Copyright (c) 2023 CercleFinance.com. All rights reserved.